NasdaqGS:ASRT

Stock Analysis Report

Executive Summary

Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States.


Snowflake Analysis

Fair value with imperfect balance sheet.


Similar Companies

Share Price & News

How has Assertio Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ASRT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.9%

ASRT

5.5%

US Pharmaceuticals

10.5%

US Market


1 Year Return

-87.2%

ASRT

-12.2%

US Pharmaceuticals

-11.5%

US Market

Return vs Industry: ASRT underperformed the US Pharmaceuticals industry which returned -12.2% over the past year.

Return vs Market: ASRT underperformed the US Market which returned -11.5% over the past year.


Shareholder returns

ASRTIndustryMarket
7 Day-7.9%5.5%10.5%
30 Day-38.1%-10.3%-15.4%
90 Day-53.2%-16.7%-21.4%
1 Year-87.2%-87.2%-10.0%-12.2%-9.6%-11.5%
3 Year-94.8%-94.8%7.0%-0.7%12.6%5.4%
5 Year-97.1%-97.1%11.0%-1.3%32.8%18.1%

Price Volatility Vs. Market

How volatile is Assertio Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Assertio Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ASRT ($0.65) is trading below our estimate of fair value ($14.24)

Significantly Below Fair Value: ASRT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ASRT is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: ASRT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ASRT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ASRT is good value based on its PB Ratio (0.9x) compared to the US Pharmaceuticals industry average (2.5x).


Next Steps

Future Growth

How is Assertio Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

28.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ASRT's forecast earnings growth is above the savings rate (1.7%).

Earnings vs Market: Insufficient data to determine if ASRT's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ASRT's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ASRT's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ASRT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Assertio Therapeutics performed over the past 5 years?

-30.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ASRT is currently unprofitable.

Growing Profit Margin: ASRT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ASRT is unprofitable, and losses have increased over the past 5 years at a rate of -30.1% per year.

Accelerating Growth: Unable to compare ASRT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ASRT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.2%).


Return on Equity

High ROE: ASRT has a negative Return on Equity (-374.76%), as it is currently unprofitable.


Next Steps

Financial Health

How is Assertio Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ASRT's short term assets ($104.0M) do not cover its short term liabilities ($184.6M).

Long Term Liabilities: ASRT's short term assets ($104.0M) do not cover its long term liabilities ($284.7M).


Debt to Equity History and Analysis

Debt Level: ASRT's debt to equity ratio (606.1%) is considered high.

Reducing Debt: ASRT's debt to equity ratio has increased from 63.1% to 606.1% over the past 5 years.


Balance Sheet

Inventory Level: ASRT has a low level of unsold assets or inventory.

Debt Coverage by Assets: ASRT's debt is not covered by short term assets (assets are 0.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ASRT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ASRT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 29.4% per year.


Next Steps

Dividend

What is Assertio Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ASRT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ASRT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ASRT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ASRT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ASRT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Art Higgins (63yo)

3s

Tenure

US$4,784,027

Compensation

Mr. Arthur Joseph Higgins, also known as Art, has been Chief Executive Officer, President and Director of Depomed, Inc. since March 28, 2017. Mr. Higgins founded Ascendancy Healthcare, Inc. in 2011 and ser ...


CEO Compensation Analysis

Compensation vs Market: Art's total compensation ($USD4.78M) is above average for companies of similar size in the US market ($USD601.33K).

Compensation vs Earnings: Art's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Arthur Higgins
CEO, President & Director3yrsUS$4.78m0.52% $274.8k
Daniel Peisert
CFO, Principal Accounting Officer & Senior VP1.25yrsUS$955.40k0.13% $67.1k
Stanley Bukofzer
Senior VP and Chief Scientific & Technical Officer1yrUS$2.33m0.055% $29.2k
Sharon Larkin
Senior Vice President of Human Resources & Administration2.17yrsno datano data
Amar Murugan
Senior VPno datano datano data
Mark Booth
Senior VP & Chief Commercial Officer2.33yrsno datano data
Max Nemmers
Director of Human Resourcesno datano datano data

2.2yrs

Average Tenure

59yo

Average Age

Experienced Management: ASRT's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Arthur Higgins
CEO, President & Director3yrsUS$4.78m0.52% $274.8k
Peter Staple
Independent Director16.33yrsUS$275.00k0.22% $118.4k
William McKee
Independent Director3yrsUS$276.00k0.035% $18.4k
James Fogarty
Independent Chairman of the Board3yrsUS$288.00k0.083% $43.7k
James Tyree
Independent Director3.42yrsUS$273.00k0.050% $26.7k
Heather Mason
Independent Director1.08yrsno data0.018% $9.4k
Karen Dawes
Independent Director11.92yrsUS$263.50k0.075% $39.5k
David Wheadon
Director0.50yrno datano data
James Galeota
Independent Director1yrno datano data

3.0yrs

Average Tenure

60.5yo

Average Age

Experienced Board: ASRT's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.9%.


Top Shareholders

Company Information

Assertio Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Assertio Therapeutics, Inc.
  • Ticker: ASRT
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$52.837m
  • Shares outstanding: 81.29m
  • Website: https://www.assertiotx.com

Number of Employees


Location

  • Assertio Therapeutics, Inc.
  • 100 South Saunders Road
  • Suite 300
  • Lake Forest
  • Illinois
  • 60045
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ASRTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDDec 1997
DPOADB (Deutsche Boerse AG)YesCommon StockDEEURDec 1997

Biography

Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The company offers Gralise (gabapentin), a once daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; and Zipsor (diclofenac potassium liquid filled capsules), a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain. It also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to require daily, around-the-clock, and long term opioid treatment, including neuropathic pain related to diabetic peripheral neuropathy in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, the company offers long-acting cosyntropin, an alcohol-free formulation of synthetic adrenocorticotropic hormone. Assertio Therapeutics, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018. Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/28 01:38
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.